Figure 5.

HXR9 retards LNCaP tumour growth in vivo. (a) Growth curve for LNCaP tumours treated intratumorally with a single dose of HXR9 (9 mice) or CXR9 (8 mice) when the tumour volume reached 100 mm3, followed by further doses if the tumour recurred. Error bars show the SEM. “Relative tumour volume” refers to the fold change in tumour size from the time of the first injection. (b) Top panels, sections through LNCaP tumours from mice treated with low dose (1 mg/Kg) FITC-HXR9. Top left, fluorescent view showing HXR9-FITC distribution (green). Top right, the same section under light microscopy. Scale bar: 100 μm. Bottom panels, sections through LNCaP tumours from mice treated with 100 mg/Kg HXR9 or CXR9. The CXR9 treated section shows highly undifferentiated tumour cells, whilst the HXR9 section shows the remains of dead tumour cells. Scale bar: 20 μm. (c) Expression of cFos in tumours treated with HXR9 or CXR9 2 hours prior to their excision, shown as a ratio between cFos and GAPDH transcripts detected by QPCR (x10,000).

Morgan et al. BMC Urology 2014 14:17   doi:10.1186/1471-2490-14-17
Download authors' original image